The FDA mix therapy approval of dolutegravir and rilpivirine is indicated for Grown ups with HIV-one bacterial infections whose virus is now suppressed (Administration of significant doses of tenofovir is claimed to supply bone toxicity reported as osteomalacia and lessened bone mineral density and to create some diploma of renal toxicity.Introduct